Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Obesity and Diabetes Mellitus, Type 2: early-phase trial registry

1 of 2 indexed Obesity and Diabetes Mellitus, Type 2 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Obesity and Diabetes Mellitus, Type 2: 2 US clinical trials tracked, 1 recruiting.

Obesity and Diabetes Mellitus, Type 2 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 1 of these trials.

Enrollment posture brief

Registry condition obesity-and-diabetes-mellitus-type-2

OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Obesity and Diabetes Mel (th…50%
Open-enrollment share among volume-matched conditions near Obesity and Diabetes Mellitus, Type 2

Obesity and Diabetes Mellitus, Type 2 lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Obesity and Diabetes Mellitus, Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Obesity and Diabetes Mellitus, Type 2 is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Obesity and Diabetes Mellitus, Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

JNJ-64565111 Dose Level 3 Drug
1 trials
JNJ-64565111 Dose Level 2 Drug
1 trials
JNJ-64565111 Dose Level 1 Drug
1 trials
PATHS-UP Mobile Phone Application Behavioral
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Obesity and Diabetes Mellitus, Type 2 trials. A trial with sites in several states counts in each.

Texas 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
Nevada 1 trials
Michigan 1 trials
Maryland 1 trials
Kansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Obesity and Diabetes Mellitus, Type 2 page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Obesity and Diabetes Mellitus, Type 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Janssen Research & Development sponsors the most Obesity and Diabetes Mellitus, Type 2 trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obesity and Diabetes Mellitus, Type 2 condition card totals 2 registered trials; most-linked intervention JNJ-64565111 Dose Level 3; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.